Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.53 |
| ▸ | MME | P08473 | 1/20 | 0.53 |
| ▸ | ITGB3 | P05106 | 12/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 11/20 | 0.52 |
| ▸ | ITGAV | P06756 | 2/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 1/20 | 0.48 |
| ▸ | TACR1 | P25103 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1712913 | 1.00 | ACE (0.53) | ACEMMEITGB3ITGA2BITGAV | |
| SCHEMBL2218273 | 0.91 | ALDH1A1 (0.53) | CTSLCTSBCTSS | |
| SCHEMBL2218264 | 0.91 | ALDH1A1 (0.53) | CTSLCTSBCTSS | |
| SCHEMBL8250720 | 0.84 | PTPN1 (0.49) | ACEMME | |
| SCHEMBL8445565 | 0.84 | ECE1 (0.59) | MMEITGB3ITGA2BITGAVCTSL | |
| SCHEMBL11032508 | 0.83 | ACE (0.60) | ACEMMEITGB3ITGA2BITGAV | |
| SCHEMBL8657006 | 0.83 | ACE (0.60) | ACEMMEITGB3ITGA2BITGAV | |
| SCHEMBL7372270 | 0.80 | TACR1 (0.68) | MMEITGB3ITGA2BCTSLCTSB | |
| SCHEMBL219151 | 0.80 | TACR1 (0.68) | MMEITGB3ITGA2BCTSLCTSB | |
| SCHEMBL479010 | 0.80 | TACR1 (0.68) | MMEITGB3ITGA2BCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382306-B2 | Octapeptide compounds derived from somatostatin and the therapeutic use thereof | IPSEN PHARMA S.A.S. (FR) | 2016-07-05 | — | — | US | disclosed |
| EP-2344529-B1 | NOVEL OCTAPEPTIDE COMPOUNDS DERIVED FROM SOMATOSTATIN AND THERAPEUTIC USE THEREOF | IPSEN PHARMA SAS (FR) | 2013-06-05 | — | — | EP | disclosed |
| CN-102171246-A | Novel octapeptide compounds derived from somatostatin and therapeutic uses thereof | IPSEN PHARMA SAS | 2011-08-31 | — | — | CN | disclosed |
| US-20110178013-A1 | NOVEL OCTAPEPTIDE COMPOUNDS DERIVED FROM SOMATOSTATIN AND THE THERAPEUTIC USE THEREOF | IPSEN PHARMA S.A.S. (FR) | 2011-07-21 | — | — | US | disclosed |
| EP-2344529-A1 | NOVEL OCTAPEPTIDE COMPOUNDS DERIVED FROM SOMATOSTATIN AND THERAPEUTIC USE THEREOF | IPSEN PHARMA S.A.S. (FR) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010037930-A1 | NOVEL OCTAPEPTIDE COMPOUNDS DERIVED FROM SOMATOSTATIN AND THERAPEUTIC USE THEREOF | IPSEN PHARMA S.A.S. (FR) | 2010-04-08 | — | — | WO | disclosed |
| EP-2168983-A1 | New octapeptide compounds and their therapeutic use | IPSEN PHARMA (FR) | 2010-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178013-A1 | NOVEL OCTAPEPTIDE COMPOUNDS DERIVED FROM SOMATOSTATIN AND THE THERAPEUTIC USE THEREOF | SSTR5, SSTR1, SSTR3 | ACE 1891/4885MME 420/4885ITGB3 3808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.